Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252196 | 0.90 | VNN1 (0.43) | DDR1VNN1SMARCA2SMARCA4MEN1 | |
| SCHEMBL30016958 | 0.81 | SMARCA2 (0.49) | DDR1VNN1SMARCA2SMARCA4LMNA | |
| SCHEMBL16690807 | 0.81 | SMARCA2 (0.49) | DDR1VNN1SMARCA2SMARCA4LMNA | |
| SCHEMBL28019417 | 0.80 | VNN1 (0.58) | DDR1VNN1SMARCA2SMARCA4LOXL2 | |
| SCHEMBL15720866 | 0.80 | JMJD6 (0.52) | VNN1MEN1KMT2A | |
| SCHEMBL29427285 | 0.79 | KDM5C (0.55) | KDM4EVNN1SMARCA2SMARCA4LOXL2 | |
| SCHEMBL503171 | 0.79 | KDM5C (0.55) | KDM4EVNN1SMARCA2SMARCA4LOXL2 | |
| SCHEMBL13890754 | 0.77 | KDM4E (0.47) | KDM4EDBHGAARECQLLOXL2 | |
| SCHEMBL25221330 | 0.77 | VNN1 (0.46) | DDR1VNN1SMARCA2SMARCA4LMNA | |
| SCHEMBL29427234 | 0.77 | LOXL2 (0.49) | DDR1VNN1SMARCA2SMARCA4LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | DDR1 535/4885KDM4E 4674/4885DBH 805/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | DDR1 535/4885KDM4E 4674/4885DBH 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.